SCHEMBL19858206

SCHEMBL19858206

O=[N+]([O-])c1ccc(CO)cc1NCC1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 13/20 0.46
▸ ALDH1A1 P00352 9/20 0.46
▸ MAPK1 P28482 2/20 0.42
▸ HTT P42858 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ CYP1A2 P05177 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ ALOX12 P18054 1/20 0.41
▸ HCAR3 P49019 1/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ PTGER4 P35408 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19858188 0.93 MAPT (0.42) MAPTALDH1A1MAPK1HTTLMNA
SCHEMBL18075569 0.92 PTGER4 (0.44) MAPTALDH1A1MAPK1HTTCYP1A2
SCHEMBL18075365 0.90 HCAR3 (0.47) MAPTALDH1A1MAPK1HTTLMNA
SCHEMBL18075181 0.87 MAPT (0.42) MAPTALDH1A1MAPK1HTTLMNA
SCHEMBL18075253 0.85 MAPT (0.45) MAPTALDH1A1MAPK1HTTLMNA
SCHEMBL18075301 0.83 HCAR3 (0.46) MAPTALDH1A1MAPK1HTTHCAR3
SCHEMBL16035315 0.82 PTGER4 (0.45) MAPTALDH1A1MAPK1HTTLMNA
SCHEMBL19858275 0.82 MAPT (0.49) MAPTALDH1A1MAPK1HTTLMNA
SCHEMBL19857884 0.82 MAPT (0.61) MAPTALDH1A1MAPK1HTTLMNA
SCHEMBL19857882 0.82 MAPT (0.61) MAPTALDH1A1MAPK1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11053212-B2 Benzimidazole derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-07-06 — — US disclosed
US-20200039953-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-02-06 — — US disclosed
US-10442786-B2 Benzimidazole derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-10-15 — — US disclosed
EP-3549939-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2019-10-09 — — EP disclosed
EP-3271349-B1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2019-05-15 — — EP disclosed
US-20180044317-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442786-B2 Benzimidazole derivatives as bromodomain inhibitors BRD4, BRD1, BRPF3 MAPT 3681/4885ALDH1A1 2160/4885MAPK1 1513/4885
US-20200039953-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD1, BRPF3 MAPT 3681/4885ALDH1A1 2160/4885MAPK1 1513/4885
US-20180044317-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD1, BRPF3 MAPT 3681/4885ALDH1A1 2160/4885MAPK1 1513/4885
US-11053212-B2 Benzimidazole derivatives as bromodomain inhibitors BRD4, BRD1, BRPF3 MAPT 3681/4885ALDH1A1 2160/4885MAPK1 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback